Immunoglobulin heavy chain locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia: Rare clinical curios or potent genetic drivers?

Blood

Volumn 115, Issue 8, 2010, Pages 1490-1499

  Dyer, Martin J S ^a   Akasaka, Takashi ^a   Capasso, Melania ^a   Dusanjh, Palminder ^a   Lee, Yin Fai ^a   Karran, E Loraine ^a   Nagel, Inga ^b   Vater, Inga ^b   Cario, Gunnar ^c   Siebert, Reiner ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CCAAT ENHANCER BINDING PROTEIN; CYTOKINE; CYTOKINE RECEPTOR LIKE FACTOR 2; ERYTHROPOIETIN RECEPTOR; IMMUNOGLOBULIN HEAVY CHAIN; INHIBITOR OF DNA BINDING 4; NUCLEIC ACID BINDING PROTEIN; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; CRLF2 PROTEIN, HUMAN; CYTOKINE RECEPTOR; ID4 PROTEIN, HUMAN; INHIBITOR OF DIFFERENTIATION PROTEIN; ONCOPROTEIN; TEL AML1 FUSION PROTEIN; TEL-AML1 FUSION PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CELL TRANSFORMATION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; EPIGENETICS; FETUS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DELETION; GENE EXPRESSION; GENE LOCUS; GENETICS; GENOMICS; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MOLECULAR CLONING; MOUSE; MULTIGENE FAMILY; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; ACUTE DISEASE; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; METABOLISM; QUANTITATIVE TRAIT LOCUS; REVIEW;

ACUTE DISEASE; ANIMALS; B-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; CORE BINDING FACTOR ALPHA 2 SUBUNIT; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIESIS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; INHIBITOR OF DIFFERENTIATION PROTEINS; ONCOGENE PROTEINS, FUSION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; QUANTITATIVE TRAIT LOCI; RECEPTORS, CYTOKINE; RECEPTORS, ERYTHROPOIETIN; TRANSLOCATION, GENETIC;

EID: 77949910163     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-09-235986     Document Type: Article

References (87)

1. Nowell PC. Discovery of the Philadelphia chromosome: a personal perspective. J Clin Invest. 2007;117(8):2033-2035. (Pubitemid 47219542)
2. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007;7(4):233-245. (Pubitemid 46480968)
3. Borrow J, Goddard AD, Sheer D, Solomon E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome-17. Science. 1990;249(4976):1577-1580.
4. Rabbitts TH. Commonality but diversity in cancer gene fusions. Cell. 2009;137(3):391-395.
5. Forster A, Pannell R, Drynan LF, et al. Engineering de novo reciprocal chromosomal translocations associated with MII to replicate primary events of human cancer. Cancer Cell. 2003;3(5):449-458. (Pubitemid 38340292)
6. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112(13):4808-4817.
7. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458(7239):719-724.
8. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008;456(7218):66-72.
9. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058- 1066.
10. Dang L, WhiteDW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-744.
11. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318(5853):1108-1113. (Pubitemid 350134889)
12. Bellido M, Aventin A, Lasa A, et al. Id4 is deregulated by a t(6;14)(p22;q32) chromosomal translocation in a B-cell lineage acute lymphoblastic leukemia. Haematologica. 2003;88(9):994-1001. (Pubitemid 37151150)
13. Chapiro E, Russell L, Radford-Weiss I, et al. Overexpression of CEBPA resulting from the translocation t(14;19)(q32;q13) of human precursor B acute lymphoblastic leukemia. Blood. 2006;108(10):3560-3563.
14. Akasaka T, Balasas T, Russell LJ, et al. Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood. 2007;109:3451-3461. (Pubitemid 46572535)
15. Russell LJ, Akasaka T, Majid A, et al. t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood. 2008;111(1):387-391.
16. Russell LJ, De Castro DG, Griffiths M, et al. A novel translocation, t(14;19)(q32;p13), involving IGH@ and the cytokine receptor for erythropoietin. Leukemia. 2009;23(3):614-617.
17. Russell LJ, Capasso M, Vater I, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B cell precursor acute lymphoblastic leukemia. Blood. 2009;114(13):2688-2698.
18. Willis TG, Dyer MJS. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood. 2000;96(3):808-822. (Pubitemid 30618048)
19. Jhunjhunwala S, van Zelm MC, Peak MM, Murre C. Chromatin architecture and the generation of antigen receptor diversity. Cell. 2009;138(3):435-448.
20. Mundt CA, Nicholson IC, Zou XG, Popov AV, Ayling C, Bruggemann M. Novel control motif cluster in the IgH delta-gamma 3 interval exhibits B cell-specific enhancer function in early development. J Immunol. 2001;166(5):3315-3323.
21. Dyer MJS, Heward JM, Zani VJ, Buccheri V, Catovsky D. Unusual deletions within the immunoglobulin heavy-chain locus in acute leukemias. Blood. 1993;82(3):865-871. (Pubitemid 23221667)
22. Paulsson K, Heidenblad M, Morse H, Borg A, Fioretos T, Johansson B. Identification of cryptic aberrations and characterization of translocation breakpoints using array CGH in high hyperdiploid childhood acute lymphoblastic leukemia. Leukemia. 2006;20(11):2002-2007. (Pubitemid 44614890)
23. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453(7191):110-114.
24. Mahowald GK, Baron JM, Sleckman BP. Collateral damage from antigen receptor gene diversification. Cell. 2008;135(6):1009-1012.
25. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009;41(11):1243-1246.
26. Hertzberg L, Vendramini E, Ganmore I, et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood. 2010;115(5):1006-1017.
27. Moore S, Suttle J, Bain S, Story C, Rice M. Acute lymphoblastic leukemia characterized by t(8;14) (q11.2;q32). Cancer Genet Cytogenet. 2003;141(1):1-4. (Pubitemid 36165189)
28. Lundin C, Heldrup J, Ahlgren T, Olofsson T, Johansson B. B-cell precursor t(8;14)(q11;q32)-positive acute lymphoblastic leukemia in children is strongly associated with Down syndrome or with a concomitant Philadelphia chromosome. Eur J Haematol. 2009;82(1):46-53.
29. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
30. Sonoki T, Iwanaga E, Mitsuya H, Asou N. Insertion of microRNA-125b-1, a human homologue of lin-4, into a rearranged immunoglobulin heavy chain gene locus in a patient with precursor B-cell acute lymphoblastic leukemia. Leukemia. 2005;19(11):2009-2010. (Pubitemid 41554016)
31. Willis TG, Zalcberg IR, Coignet LJA, et al. Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood. 1998;91:1873-1881.
32. Aventin A, Sanchez J, Nomdedeu JF, et al. Novel IGHalpha translocations, t(2;14)(q14.3;q32) and t(14;17)(q32;q21), in B-cell precursor acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2008;185(1):57-59.
33. Kawamata N, Sakajiri S, Sugimoto KJ, Isobe Y, Kobayashi H, Oshimi K. A novel chromosomal translocation t(1;14)(q25;q32) in pre-B acute lymphoblastic leukemia involves the LIM homeodomain protein gene, Lhx4. Oncogene. 2002;21(32):4983-4991.
34. Pegoraro L, Palumbo A, Erikson J, et al. A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. Proc Natl Acad Sci U S A. 1984;81(22):7166-7170.
35. Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol. 2009;144(2):147-156.
36. Harrison CJ, Martineau M, Secker-Walker LM. The Leukaemia Research Fund/United Kingdom Cancer Cytogenetics Group karyotype database in acute lymphoblastic leukaemia: a valuable resource for patient management. Br J Haematol. 2001;113(1):3-10. (Pubitemid 32423294)
37. Mestas J, Hughes CCW. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172(5):2731-2738. (Pubitemid 38263654)
38. Parrish YK, Baez I, Milford TA, et al. IL-7 dependence in human B lymphopoiesis increases during progression of ontogeny from cord blood to bone marrow. J Immunol. 2009;182(7):4255-4266.
39. Leonard WJ. TSLP: finally in the limelight. Nat Immunol. 2002;3(7):605-607.
40. Levin SD, Koelling RM, Friend SL, et al. Thymic stromal lymphopoietin: a cytokine that promotes the development of IgM(+) B cells in vitro and signals via a novel mechanism. J Immunol. 1999;162(2):677-683.
41. Carpino N, Thierfelder WE, Chang MS, et al. Absence of an essential role for thymic stromal lymphopoietin receptor in murine B-cell development. Mol Cell Biol. 2004;24(6):2584-2592. (Pubitemid 38326011)
42. Al-Shami A, Spolski R, Kelly J, et al. A role for thymic stromal lymphopoietin in CD4(+) T cell development. J Exp Med. 2004;200(2):159-168. (Pubitemid 38982175)
43. Brown VI, Hulitt J, Fish J, et al. Thymic stromalderived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling. Cancer Res. 2007;67(20):9963-9970. (Pubitemid 47621246)
44. Isaksen DE, Baumann H, Zhou B, et al. Uncoupling of proliferation and Stat5 activation in thymic stromal lymphopoietin-mediated signal transduction. J Immunol. 2002;168(7):3288-3294. (Pubitemid 34250390)
45. Mullighan CG, Zhang JH, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2009;106(23):9414-9418.
46. Willman CL, Kang HN, Harvey RC, et al. Use of genomic technologies to identify novel genetic abnormalities and therapeutic targets in acute lymphoblastic leukemia. Blood. 2008;112(11):1344-1345.
47. Inthal A, Krapf G, Beck D, et al. Role of the erythropoietin receptor in ETV6/RUNX1-positive acute lymphoblastic leukemia. Clin Cancer Res. 2008;14(22):7196-7204.
48. Hystad ME, Myklebust JH, Bo TH, et al. Characterization of early stages of human B cell development by gene expression profiling. J Immunol. 2007;179(6):3662-3671.
49. Ford AM, Palmi C, Bueno C, et al. The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. J Clin Invest. 2009;119(4):826-836.
50. Hadland BK, Longmore GD. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms. J Clin Oncol. 2009;27(25):4217-4226.
51. Huang MS, Harris NL, D'Angelo HA, Hasserjian RP, Weinstein H. A 12-year-old boy with fatigue and eosinophilia: precursor B-cell acute lymphoblastic leukemia with eosinophilia and the t(5;14)(q31;q32) translocation. N Engl J Med. 2004;350(25):2604-2612.
52. Riechmann V, van Cruchten I, Sablitzky F. The expression pattern of Id4, a novel dominant negative helix-loop-helix protein, is distinct from Id1, Id2 and Id3. Nucleic Acids Res. 1994;22(5):749-755. (Pubitemid 24160899)
53. Roberts EC, Deed RW, Inoue T, Norton JD, Sharrocks AD. Id helix-loop-helix proteins antagonize Pax transcription factor activity by inhibiting DNA binding. Mol Cell Biol. 2001;21(2):524-533. (Pubitemid 32037372)
54. Kee BL. E and ID proteins branch out. Nat Rev Immunol. 2009;9(3):175-184.
55. Lasorella A, Stegmuller J, Guardavaccaro D, et al. Degradation of Id2 by the anaphase-promoting complex couples cell cycle exit and axonal growth. Nature. 2006;442(7101):471-474. (Pubitemid 44264798)
56. Jeon HM, Jin X, Lee JS, et al. Inhibitor of differentiation 4 drives brain tumor-initiating cell genesis through cyclin E and notch signaling. Genes Dev. 2008;22(15):2028-2033.
57. Cooper CL, Brady G, Bilia F, Iscove NN, Quesenberry PJ. Expression of the Id family helix-loop-helix regulators during growth and development in the hematopoietic system. Blood. 1997;89(9):3155-3165. (Pubitemid 27229798)
58. Yu L, Liu CH, Vandeusen J, et al. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet. 2005;37(3):265-274. (Pubitemid 41716253)
59. Chen SS, Johnson AJ, Claus R, Sablitzky F, Plass C, Byrd JC. Loss of Id4 accelerates CLL progression in TCL1 mice [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112(11): Abstract 3153.
60. Iavarone A, Lasorella A. ID proteins as targets in cancer and tools in neurobiology. Trends Mol Med. 2006;12(12):588-594.
61. Henke E, Perk J, Vider J, et al. Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nat Biotechnol. 2008;26(1):91-100.
62. Sonoki T, Harder L, Horsman DE, et al. Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. Blood. 2001;98(9):2837-2844.
63. Gesk S, Klapper W, Martin-Subero J, et al. A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. Blood. 2006;108(3):1109-1110. (Pubitemid 44154656)
64. Gery S, Tanosaki S, Hofmann WK, Koppel A, Koeffler HP. C/EBP delta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation. Oncogene. 2005;24(9):1589-1597. (Pubitemid 40396088)
65. Nerlov C. The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. Trends Cell Biol. 2007;17(7):318-324.
66. Zhang P, Iwasaki-Arai J, Iwasaki H, et al. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity. 2004;21(6):853-863.
67. Xie HF, Ye M, Feng R, Graf T. Stepwise reprogramming of B cells into macrophages. Cell. 2004;117(5):663-676.
68. Laiosa CV, Stadtfeld M, Graf T. Determinants of lymphoid-myeloid lineage diversification. Annu Rev Immunol. 2006;24:705-738.
69. Koschmieder S, Halmos B, Levantini E, Tenen DG. Dysregulation of the C/EBP alpha differentiation pathway in human cancer. J Clin Oncol. 2009;27(4):619-628.
70. Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J. Brief report: mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med. 2004;351(23):2403-2407. (Pubitemid 40500184)
71. Perrotti D, Cesi V, Trotta R, et al. BCR-ABL suppresses C/EBP alpha expression through inhibitory action of hnRNP E2. Nat Genet. 2002;30(1):48-58.
72. Rosenbauer F, Tenen DG. Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol. 2007;7(2):105-117. (Pubitemid 46174858)
73. Papaemmanuil E, Hosking FJ, Vijayakrishnan J, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet. 2009;41(9):1006-1010.
74. Bousquet M, Quelen C, Rosati R, et al. Myeloid cell differentiation arrest by miR-125b-1 in myelodysplasic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med. 2008;205(11):2499-2506.
75. Le MTN, Teh C, Shyh-Chang N, et al. MicroRNA-125b is a novel negative regulator of p53. Genes Dev. 2009;23(7):862-876.
76. Malumbres R, Sarosiek KA, Cubedo E, et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood. 2009;113(16):3754-3764.
77. Malinge S, Izraeli S, Crispino JD. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood. 2009;113(12):2619-2628.
78. Klusmann JH, Janikova K, Li Z, Orkin SH, Reinhardt D. Chromosome 21-encoded miR-125b and its role in the development of myeloid leukemia in children with Down's syndrome [abstract]. Blood. 2007;110(11):220.
79. Gefen N, Binder V, Zaliova M, et al. Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53. Leukemia. 2010;24(1):89-96.
80. Fine BM, Stanulla M, Schrappe M, et al. Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. Blood. 2004;103(3):1043-1049. (Pubitemid 38129570)
81. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030-1043.
82. Sustmann C, Flach H, Ebert H, Eastman Q, Grosschedl R. Cell-type-specific function of BCL9 involves a transcriptional activation domain that synergizes with beta-catenin. Mol Cell Biol. 2008;28(10):3526-3537.
83. Sampietro J, Dahlberg CL, Cho US, Hinds TR, Kimelman D, Xu WQ. Crystal structure of a betacatenin/BCL9/Tcf4 complex. Mol Cell. 2006;24(2):293-300.
84. Kobel M, Weidensdorfer D, Reinke C, et al. Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma. Oncogene. 2007;26(54):7584-7589. (Pubitemid 350207710)
85. Mayr C, Bartel DP. Widespread shortening of 3′ UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell. 2009;138(4):673-684.
86. Hara E, Hall M, Peters G. Cdk2-dependent phosphorylation of Id2 modulates activity of E2A-related transcription factors. EMBO J. 1997;16(2):332-342. (Pubitemid 27049390)
87. Matsumura ME, Lobe DR, McNamara CA. Contribution of the helix-loop-helix factor Id2 to regulation of vascular smooth muscle cell proliferation. J Biol Chem. 2002;277(9):7293-7297.